uniQure (QURE) Stock Price, News & Analysis

uniQure logo
$19.35 -0.88 (-4.35%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$20.51 +1.16 (+6.00%)
As of 11/20/2026 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About uniQure Stock (NASDAQ:QURE)

Advanced

Key Stats

Today's Range
$19.00
▼
$21.60
50-Day Range
$19.35
▼
$45.28
52-Week Range
$8.73
▼
$51.72
Volume
2.10 million shs
Average Volume
1.93 million shs
Market Capitalization
$1.36 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$55.58
Consensus Rating
Moderate Buy

Company Overview

uniQure N.V. is a biotechnology company that develops gene therapies for serious genetic and other diseases. The company uses adeno-associated virus (AAV) vectors to deliver genetic material to patients’ cells, with research and development operations in the United States and the Netherlands.

Its programs have targeted conditions including Huntington’s disease, epilepsy and hemophilia B. uniQure developed the gene therapy now known as Hemgenix for hemophilia B; it is commercialized by CSL Behring under a partnership. The company’s pipeline also includes therapies being evaluated in clinical studies.

Founded in the Netherlands in 1998, uniQure traces its origins to Amsterdam Molecular Therapeutics. Its Glybera therapy became the first gene therapy to receive marketing authorization in the European Union, though it was later withdrawn from the market.

AI Generated. May Contain Errors.

uniQure Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
57th Percentile Overall Score

QURE MarketRank™: 
2.83127456485 of 5 stars

uniQure scored higher than 57% of companies evaluated by MarketBeat, and ranked 386th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    uniQure has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 11 buy ratings, 3 hold ratings, and 1 sell rating.

  • Upside Potential

    uniQure has a consensus price target of $55.58, representing about 187.3% upside from its current price of $19.35.

  • Amount of Analyst Coverage

    uniQure has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about uniQure's stock forecast and price target.
  • Earnings Growth

    Earnings for uniQure are expected to grow in the coming year, from ($3.79) to ($3.59) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of uniQure is -5.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of uniQure is -5.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    uniQure has a P/B Ratio of 4.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    12.72% of the float of uniQure has been sold short.
  • Short Interest Ratio / Days to Cover

    uniQure has a short interest ratio ("days to cover") of 6.39.
  • Change versus previous month

    Short interest in uniQure has recently decreased by 2.51%, indicating that investor sentiment is improving.
  • Dividend Yield

    uniQure does not currently pay a dividend.

  • Dividend Growth

    uniQure does not have a long track record of dividend growth.

  • News Sentiment

    uniQure has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for uniQure this week, compared to 9 articles on an average week.
  • Search Interest

    Only 9 people have searched for QURE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, uniQure insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    4.65% of the stock of uniQure is held by insiders.

  • Percentage Held by Institutions

    78.83% of the stock of uniQure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about uniQure's insider trading history.
Receive QURE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

QURE Stock News Headlines

uniQure N.V. (NASDAQ:QURE) Stock Has Average Price Target of $56.83
uniQure (NASDAQ:QURE) Stock Price Target Cut by HC Wainwright
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
Is uniQure (QURE) Priced Beyond Its Book Value Support?
uniQure (QURE) Q3 2026 Earnings Call Transcript
See More Headlines

QURE Stock Analysis - Frequently Asked Questions

uniQure's stock was trading at $23.93 at the beginning of the year. Since then, QURE shares have decreased by 19.1% and is now trading at $19.35.

uniQure N.V. (NASDAQ:QURE) released its quarterly earnings results on Wednesday, November, 4th. The biotechnology company reported ($0.88) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.04. The biotechnology company had revenue of $5.20 million for the quarter, compared to the consensus estimate of $6.18 million. uniQure had a negative trailing twelve-month return on equity of 96.34% and a negative net margin of 1,154.84%.
Read the conference call transcript
.

uniQure (QURE) raised $76 million in an initial public offering on Wednesday, February 5th 2014. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share.

Top institutional investors of uniQure include State Street Corp (3.68%), Two Seas Capital LP (1.91%), Goldman Sachs Group Inc. (1.45%) and Assenagon Asset Management S.A. (1.00%). Insiders that own company stock include Matthew C Kapusta, Christian Klemt, Walid Abi-Saab, Jeannette Potts, Kylie O'keefe, Pierre Caloz, Madhavan Balachandran, Jeremy P Springhorn, David D Meek, Leonard E Post, Rachelle Suzanne Jacques, Robert Gut and Jack Kaye.
View institutional ownership trends
.

Shares of QURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that uniQure investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Salesforce (CRM), Tesla (TSLA) and Intel (INTC).

Company Calendar

Last Earnings
11/04/2026
Today
11/22/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:QURE
CIK
1590560
Employees
221
Year Founded
1868

Price Target and Rating

High Price Target
$75.00
Low Price Target
$28.00
Potential Upside/Downside
+187.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
16 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.51)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$198.97 million
Net Margins
-1,154.84%
Pretax Margin
-1,159.36%
Return on Equity
-96.34%
Return on Assets
-26.40%

Debt

Debt-to-Equity Ratio
0.17
Current Ratio
11.52
Quick Ratio
11.52

Sales & Book Value

Annual Sales
$16.10 million
Price / Sales
84.30
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.20 per share
Price / Book
4.61

Miscellaneous

Outstanding Shares
70,140,000
Free Float
66,878,000
Market Cap
$1.36 billion
Optionable
Optionable
Beta
1.14

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:QURE) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners